With twin platform technologies, Interprotein provides highly active modulators for protein-protein interaction (PPI) targets.
Our proprietary technology (INTENDD®) is built upon a different conceptual foundation from MD-based docking simulation methods, generating highly active compounds with unique scaffolds.
On the other hand, our newly constructed libraries of helix-loop-helix peptide achieved a near 100% success rate in identifying strong binders with KD values in low nanomolar range.
Change drug discovery
With INTENDD®, we aim to develop and provide an in silico drug design platform specialized
for producing small molecule PPI modulators, and extend this technology
to establish an AI-based drug discovery program.
Alternatively, we have developed extremely diverse libraries of helix-loop-helix
peptides for phage-display screening. Phage-displayed random peptide screening
enables us to achieve a near 100% success rate in identifying active peptides
with high affinity and high specificity to PPI targets. In addition, we
can easily modulate pharmacokinetic profiles via multiple approaches.
Through collaborative R&D efforts, we will fully exploit our twin
technologies for small molecules and peptides to identify highly active
modulators against previously intractable PPI interfaces. We commit to
turning current biologics (antibodies and soluble receptors)-based PPI
inhibitions into more patient-friendly therapies with small molecule and/or
peptide PPI modulators to change patients’ lives.
||Introduction of Interprotein Corporation in BenchSci’s expanding list of exceptional Biotech companies engaged in Artificial Intelligence
||Joint research project “Development of Radioprotection Drug” has won the Osaka City Innovative Creation Grant
||AI-guided INTENDD®, Interprotein’s AI drug discovery platform based on deep learning of binding structures of small molecules and target proteins, is transitioning into a practical stage
||"Pharmacological activity value prediction system of compound by AI (depth learning)" has been registered as program copyright.
||A paragraph on AI-guided INTENDD® has been added.
||We will be attending BioJapan 2017 from October 11-13 (Wed-Fri).
||Dr. Takeshi Tanaka, the general manager of Drug Design lab gave a presentation
titled "The Contribution of Entropy in Drug-Protein Binding"
at the CBI annual meeting 2017 on 3rd October.
||On October 10th, we'll be attending the "European Biotech and Pharma Partnering Conference, Osaka 2017".
||Dr. Takeshi Tanaka, the manager of Drug Design lab, published an article in the journal of Medical Science Digest.
||We have renewed our web site! and also started Twitter, please follow us!
||Dr. Matsuzaki, the head of Drug Design lab, contributed a section to the Encyclopedia of Artificial Intelligence (The Japanese Society for Artificial Intelligence Edition), which was published on July 10, 2017.
||On July 25th, Masato Hosoda, CEO, will give a presentation at the KANSAI seminar titled “Kansai in the new era opened by AI” hosted by BBTower, Inc.
||On July 24th, Masaro Hosoda, CEO, will give a presentation at a symposium entitled “Realization of a society of health and longevity via application of AI and Big-data” hosted by Institution for Biomedical Research and Innovation (IBRI)
||On July 7th, Masato Hosoda, CEO, will give a presentation at “Mie university - jurisprudence and medical science joint symposium” hosted by Graduate School of Medicine, Mie University
||Dr. Matsuzaki, the head of Drug Design Lab, gave a poster presentation titled “True landscape of drug-protein binding” at JCUP VIII, an annual science meeting held by OpenEye Scientific Software.
||New York Medical College and Interprotein Announce Research Partnership Agreement on Drug Discovery Research for small molecule PPI Inhibitors
||Interprotein Corporation and A.I. Squared, Inc. Sign a Joint Research and Development AI Drug Discovery Agreement